繁體
简体中文
繁體中文

推特 TWTR

已收盤 11-16 16:00:00 美东时间

53.70

0.000

0.00%

华盛通華盛通
立即下載
  • 最 高--
  • 今 開--
  • 成交量 0股
  • 最 低 --
  • 昨 收 53.70
  • 總市值 4108.05万
  • 52周最高 54.57
  • 市盈率 --
  • 換手率 0.00%
  • 52周最低 31.30
  • 委 比 0.00%
  • 總股本 0.01亿
  • 歷史最高 80.75
  • 量 比 0
  • 振 幅 0.00%
  • 歷史最低 13.725
  • 每 手 1
  • 風險率 0.00%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • 周末读物 | 黄仁勋联合70家巨头的反垄断檄文:硅谷“大分裂”背后,一场关乎算力基本盘的生死博弈

    黄仁勋联合70家巨头的反垄断檄文:硅谷“大分裂”背后,一场关乎算力基本盘的生死博弈

    08-08 16:36

  • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Praxis Precision Medicines granted 7,318 restricted stock units to 29 new non-executive employees under its 2024 Inducement Plan. The awards vest annually over four years and are intended to incentivize employment. The company focuses on CNS disorders using genetic insights and proprietary platforms.

    08-04 20:01

  • Vishay Intertechnology TSOP15300 Series IR Receivers Support All Major Remote Control Codes

    Vishay Intertechnology introduced the TSOP15300 series of IR receiver modules, featuring a wide 30 kHz to 68 kHz modulation frequency range. These devices enable universal remote control solutions by supporting all major remote codes, reducing component counts, and saving board space. Designed for consumer electronics, they offer immunity to interference and reliable transmission up to 18 meters. The modules integrate a photodetector, preamplifie...

    08-04 15:00

  • Bitdeer Announces $4.7 Billion, 16-Year AI/HPC Data Center Lease for Tydal, Norway Campus

    Bitdeer AI and Volta have signed a 16-year lease agreement for a large-scale AI data center in Norway, with a potential 8-year extension. The deal is valued at $4.7 billion over 16 years, rising to $8 billion with the extension. The 121 IT MW facility, powered by NVIDIA GPUs, will be among Norway's largest and most efficient AI data centers, using 100% renewable energy with a PUE of 1.1. Credit support of $1.3 billion is provided by J.P. Morgan a...

    08-04 12:00

  • CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

    CytomX Therapeutics, Inc. has appointed Alejandra Carvajal as its new Chief Legal Officer. With over two decades of legal experience in the biotechnology sector, Carvajal will support the company's strategic and operational initiatives. She previously served as Chief Legal Officer at Mersana Therapeutics and Momenta Pharmaceuticals. CytomX, a clinical-stage oncology-focused biopharmaceutical company, is advancing its PROBODY® therapeutic platform...

    08-03 12:00

  • Bitdeer Announces Second Quarter 2026 Earnings Conference Call for August 10th 2026

    Bitdeer Technologies Group has scheduled its Q2 2026 earnings conference call for August 10, 2026, at 8:00 AM EST. The call will discuss financial and operational results for the quarter ended June 30, 2026, followed by a Q&A session. The earnings release will be available at 7:00 AM EST on the same day on the Company’s Investor Relations website. Participants can join via a live webcast or phone, with registration required in advance. An archive...

    08-01 04:30

  • Precipio Announces Q2-2026 Shareholder Update Call

    Precipio, Inc. will host a Q2-2026 shareholder update call on August 17, 2026, at 5:00 PM ET. The call will cover the company’s current core businesses and include a live Q&A session. CEO Ilan Danieli expressed excitement about Q2 results, highlighting progress in customer acquisition, pipeline expansion, and business growth. Investors can submit questions in advance via email to investors@precipiodx.com or participate during the call by dialing ...

    07-31 20:00

  • Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

    Tvardi Therapeutics selected ulcerative colitis (UC) as the initial indication for its next-generation STAT3 inhibitor, TTI-109, following successful Phase 1 results showing reductions in immune cell subsets linked to UC pathology. STAT3, a key convergence point for UC-related signaling pathways, is targeted by TTI-109 to address immune dysregulation, inflammation, and tissue remodeling. Current UC therapies achieve suboptimal remission rates, an...

    07-30 11:30

  • 埃隆・马斯克与X平台广告主了结持续已久的法律纠纷

      埃隆・马斯克旗下X平台与一众广告主达成和解,这场诉讼就此落幕。该案指控玛氏、壳牌、雀巢、乐高等品牌非法抵制该社交媒体平台。   X的母公司X集团于...

    07-29 22:32

  • VALUE LINE, INC. ANNOUNCES HIGHER FISCAL YEAR 2026 EARNINGS

    Value Line, Inc. reported a 4.6% increase in net income to $21.63 million for FY 2026, with total investment gains up 98.5% to $6.43 million. Dividends rose to $1.40 per share annually, yielding 4.0%. Retained earnings, liquid assets, and shareholders’ equity all increased by 8.1%, 11.7%, and 8.2% respectively. The company offers extensive investment research services, including stock recommendations, ETF analysis, and fund advisory, with service...

    07-29 16:48